A Phase I Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Clinical Activity of RO7673396 as a Single Agent and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors Harboring RAS Mutation(s)
This study tests a new experimental medication called RO7673396 for people with advanced solid tumors that have a specific genetic change called a RAS mutation. Researchers want to find the safest and most effective dose of this medicine to help fight the cancer.
You may be able to join if you have advanced solid tumor cancer that cannot be cured, can still carry out normal daily activities, and have good organ function. However, you cannot join if you have untreated cancer in your brain, severe digestive issues, or major stomach surgeries that affect how your body absorbs medicines.
The study starts with a dose-escalation phase to find the right amount of the medicine, followed by an expansion phase to see how well it fights tumors. You will receive the study treatment while doctors closely monitor your safety, health, and how your body processes the drug.
This study is currently recruiting participants and takes place at multiple locations, including medical centers in California, Colorado, and Connecticut. Your care team will guide you through the exact schedule and location details.
- 1Testing an experimental medication called RO7673396 for advanced solid tumors
- 2Looking for the best and safest dose to shrink tumors with RAS mutations
- 3Currently recruiting patients at select medical centers in the United States
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.